^
1m
Clinical and Analytical Evaluation of the Abbott Alinity m HR HPV Assay in a New Generation First-Void Urine Collector. (PubMed, J Med Virol)
Using the HPV test's adjusted cutoff for first-void urine, no difference in clinical sensitivity or specificity was observed between first-void urine and cervical samples. These data highlight the importance of evaluating self-sample-specific cut-offs for HPV assays, previously validated on cervical samples.
Journal
|
ALINITY m HR HPV ASSAY
2ms
Multi-center evaluation of the Alinity m HR HPV assay with liquid-based cytology cervical specimens in the United States. (PubMed, Microbiol Spectr)
Extended HR HPV testing can provide additional information to triage patients for appropriate testing and follow-up.IMPORTANCEExtended genotyping for high-risk human papillomavirus (HPV) types enhances diagnostic precision by identifying additional oncogenic HPV types beyond 16 and 18 therefore offering a more nuanced risk profile. This more comprehensive detection may aid in identifying persistent infections that are more likely to progress, thereby supporting future risk-based patient management strategies.
Journal
|
ALINITY m HR HPV ASSAY • cobas® HPV test
5ms
High-Risk HPV Detection and Genotype Distribution in African American Women with Cervical Precancer and Cancer (AMP 2024)
These data demonstrate the differences in HR HPV genotype prevalence for the African American population compared to the total study population in a large U.S. clinical study. Despite the differences in genotype distribution, the Alinity m HR HPV assay demonstrated 100.0% (95% CI, 74.1%, 100.0%) sensitivity for African American women with cervical precancer and cancer.
Clinical
|
ALINITY m HR HPV ASSAY
5ms
HPV Vaccination and Its Influence on HPV Detection in Women with High-Grade Cervical Dysplasia (AMP 2024)
Due to variable HPV vaccination uptake rates, HPV molecular tests used for cervical cancer screening must be able to detect cervical dysplasia regardless of vaccine status. These data demonstrate that the clinical sensitivity of the Alinity m HR HPV assay for the detection of cervical dysplasia is equivalent to the cobas HPV test in both vaccinated and unvaccinated populations.
Clinical
|
ALINITY m HR HPV ASSAY • cobas® HPV test
5ms
Clinical and Analytical Evaluation of Self-Collected Vaginal Samples with Alinity m HR (AMP 2024)
In this study, analytical and clinical studies demonstrate that self-collected vaginal specimens can be utilized for routine cervical cancer screening with the Alinity m HR HPV assay.
Clinical
|
ALINITY m HR HPV ASSAY
5ms
Prevalence of Non-16/18/45 HPV Genotypes from the US Cohort (AMP 2024)
In the Screening population, Group A HPV52 and Group B HPV68 had the highest prevalence among the sequenced samples. In the Enriched population, Group A HPV52 again had the highest prevalence, whereas HPV56 had the highest prevalence in the Group B.
ALINITY m HR HPV ASSAY
5ms
Utility of Alinity m HR HPV Genotype Detection and Viral Load for the Disease Risk Stratification (AMP 2024)
In this study, HPV18 demonstrated the highest median difference between ≥CIN3 and ≤CIN1 (3.82 CN), followed by HPV16 (2.96 CN), Group A (2.53 CN), HPV 45 (2.23 CN), and Group B (2.09 CN).
ALINITY m HR HPV ASSAY
11ms
Clinical Performance of the Alinity M HR HPV Assay in SurePath Specimens (ASM Microbe 2024)
The Alinity m HR HPV assay demonstrated an OPA of ≥90.3% when compared to the cobas 4800 HPV test across all HR HPV genotypes and cervical cytology grades for cervical specimens collected in SurePath.
Clinical
|
ALINITY m HR HPV ASSAY • cobas® HPV test
11ms
Clinical Performance of Alinity m HR HPV Assay (ASM Microbe 2024)
In this study HPV16 and HPV18 carried the highest absolute risk followed by HPV45, Other A and Other B. These results indicate that the Alinity m HR HPV assay can effectively predict elevated risk for CIN3 or higher pathology in women 25 years or older. Our findings demonstrate the utility of the Alinity m HR HPV assay in routine cervical cancer screening.
Clinical
|
ALINITY m HR HPV ASSAY • cobas® HPV test
11ms
High Agreement Rates Observed between the Alinity m HR HPV Assay and Next Generation Sequencing for the Detection of HPV Virus (ASM Microbe 2024)
Alinity m HR HPV assay agreement using the clinical cutoff in ThinPrep was PPA ≥85.44% and NPA ≥95.35% and in SurePath PPA ≥84.00%, NPA ≥93.84%. The NGS genotyping agreement results from this study demonstrate that the Alinity m HR HPV assay with extended genotyping can be effectively included as part of a cervical cancer screening program.
Next-generation sequencing
|
ALINITY m HR HPV ASSAY
over1year
Clinical accuracy of Alinity m HR HPV assay on self- versus clinician-taken samples using the VALHUDES protocol. (PubMed, J Mol Diagn)
In conclusion, clinical sensitivity of Alinity assay on all self-sample types was similar to cervical specimens in a colposcopy referral population. Adjustment of signal-thresholds improved assay´s accuracy to detect CIN2+ in all self-sample types.
Journal
|
ALINITY m HR HPV ASSAY
over1year
Abbott receives FDA approval for HPV test to run on Alinity m, offering primary HPV screening and assessment of high-risk cancer-causing types of HPV (PRNewswire)
"Abbott...has received U.S. Food and Drug Administration (FDA) approval for its molecular human papillomavirus or HPV screening solution, adding a powerful cancer screening tool for detecting high-risk HPV infections to the Alinity m family of diagnostic assays...The Alinity m high risk (HR) HPV assay is approved as a test for HPV detection and for use in routine cervical cancer screening as per professional medical guidelines."
FDA event
|
ALINITY m HR HPV ASSAY